Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.

Abstract

Neoangiogenesis is involved in the pathophysiology of multiple myeloma and angiopoietins possibly contribute to myeloma-induced neovascularization. Bortezomib's antineoplastic potential includes an anti-angiogenic effect. We determined serum levels of angiopoietin-1 and angiopoietin-2 with ELISA pre- and post-bortezomib administration in 35 patients with relapsed/refractory multiple myeloma. Pre-bortezomib, serum angiopoietin-1 levels did not differ in patients and in healthy individuals, while serum angiopoietin-2 levels were elevated. Corresponding serum angiopoietin-1/angiopoietin-2 ratio was reduced in patients compared with controls. After treatment, serum angiopoietin-1 levels increased, while serum angiopoietin-2 levels decreased, therefore the angiopoietin-1/angiopoietin-2 ratio increased and normalized. This increase was significant in patients who responded to treatment. In conclusion, angiopoietin-1/angiopoietin-2 ratio normalization reflected response to bortezomib.

• Authors: Konstantinos Anargyrou, Evangelos Terpos, Theodoros P Vassilakopoulos, Anastasia Pouli, Sotirios Sachanas, Tatiana Tzenou, Stavroula Masouridis, Dimitrios Christoulas, Maria K Angelopoulou, Evangelia M Dimitriadou, Christina Kalpadakis, Konstantinos Tsionos, Panayiotis Panayiotidis, Meletios A Dimopoulos, Gerassimos A Pangalis, Marie-Christine Kyrtsonis, Greek Myeloma Study Group
• Journal: Haematologica (Haematologica) Vol. 93 Issue 3 Pg. 451-4 (Mar 2008) ISSN: 1592-8721 [Electronic] Italy
• PMID: 18287135 (Publication Type: Journal Article)

Chemical References

• ANGPT1 protein, human
• Angiopoietin-1
• Angiopoietin-2
• Antineoplastic Agents
• Biomarkers, Tumor
• Boronic Acids
• Neoplasm Proteins
• Protease Inhibitors
• Pyrazines
• Bortezomib
• Receptor, TIE-2

Topics

• Adult
• Aged
• Aged, 80 and over
• Angiopoietin-1 (blood)
• Angiopoietin-2 (blood)
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (blood)
• Bone Marrow (blood supply)
• Boronic Acids (therapeutic use)
• Bortezomib
• Drug Resistance, Neoplasm
• Female
• Humans
• Male
• Middle Aged
• Multiple Myeloma (blood, drug therapy, physiopathology)
• Neoplasm Proteins (blood, physiology)
• Neovascularization, Pathologic (drug therapy)
• Protease Inhibitors (therapeutic use)
• Pyrazines (therapeutic use)
• Receptor, TIE-2 (physiology)
• Salvage Therapy
• Treatment Outcome